Consumer trends towards environmentally friendly products are driving plastics industries to investigate more benign alternatives to petroleum-based polymers. In the case of adhesives, one possibility to achieve sustainable production is to use non-toxic, low-cost starches as biodegradable raw materials for adhesive production. While native starch contains only hydroxyl groups and has limited scope, chemically modified starch shows superior water resistance properties for adhesive applications. Esterified starches, starches with ester substituents, can be feasibly produced and utilized to prepare bio-based adhesives with improved water resistance. Syntheses of esterified starch materials can involve esterification, transesterification, alkylation, acetylation, succinylation, or enzymatic reactions. The main focus of this review is on the production of esterified starches and their utilization in adhesive applications (for paper, plywood, wood composites, fiberboard, and particleboard). The latter part of this review discusses other processes (etherification, crosslinking, grafting, oxidation, or utilizing biobased coupling agents) to prepare modified starches that can be further applied in adhesive production. Further discussion on the characteristics of modified starch materials and required processing methods for adhesive production is also included.
Purpose: To evaluate the optimal dosing regimens of meropenem against extended-spectrum beta-lactamase-producing Escherichia coli (ESBL E. coli) in critically ill patients with varying degrees of renal function using Monte Carlo simulation (MCS). Methods: The MCS was performed using the minimum inhibitory concentration (MIC) data from Right Laboratory and Health Screen in Naypyitaw, Myanmar, as well as reported meropenem pharmacokinetic parameters in the target population and the pharmacokinetic-pharmacodynamic index. For each dosing regimen, 10,000 virtual patients were generated to assess the probability of target attainment (PTA) and the cumulative fraction of response (CFR). The most effective dosage regimens were determined using PTA and a CFR of 90%. Results: ESBL E. coli made up 93 of the 396 clinical E. coli isolates, and they are all multidrug-resistant, with resistance to at least five antibiotic classes. The MIC50 and MIC90 were determined to be 0.25 μg/mL. The PTA was affected by five factors: creatinine clearance (CLcr), vasopressor usage, MIC, infusion time, and dosage fractionation. In patients who did not receive vasopressors, the current regimens (US-FDA and EMA) were ineffective in all renal function for MIC > 0.25μg/mL. In the subset group of CLcr > 80 mL/min for MIC 2μg/mL, the maximum total daily dose of 6g/day (2g q 8hr; 3hr infusion) was still ineffective, but 4g/day (1g q 6hr; 3hr infusion) achieved 98.96% PTA. Almost majority of the simulated regimens produced > 90% PTA in vasopressor-dependent patients with all levels of renal function, resulting in a decreased total daily dose requirement. Conclusion: For high MIC (> 1μg/mL) patients who do not use vasopressors and have a CLcr > 80 mL/min, a combination of dosage fractionation and the extended infusion was considered as an effective technique to maximize target attainment. Neither prolonged infusion nor dosage fractionation should be explored in patients using vasopressors.